Development of Bioactive Molecules for the Treatment of Alzheimer’s Disease †
Department of Quality Assurance, SVKM’s Dr. Bhanuben Nanavati College of Pharmacy, Vile Parle, Mumbai 400056, India
*
Author to whom correspondence should be addressed.
†
Presented at the 8th International Electronic Conference on Medicinal Chemistry, 1–30 November 2022; Available online: https://ecmc2022.sciforum.net/ .
Med. Sci. Forum 2022, 14(1), 7; https://doi.org/10.3390/ECMC2022-13470
Published: 1 November 2022
(This article belongs to the Proceedings of The 8th International Electronic Conference on Medicinal Chemistry)
Abstract
:A series of novel thiophene pyrazolines were designed as potential bioactive molecules against Alzheimer’s disease. The probable binding modes of these molecules in AChE were evaluated using in silico techniques, and promising molecules were then synthesized and characterized. Their biological activities were profiled to confirm their potential as multifunctional molecules for the treatment of Alzheimer’s disease by addressing multiple pathological mechanisms. While the anti-oxidant activities of the synthesized molecules needed further optimization, the series showed excellent potential in mitigating the multiple causative factors via Aβ aggregation inhibition, AChE inhibition, metal chelation, and inhibition of advanced glycation products.
Supplementary Materials
The following are available online at https://www.mdpi.com/article/10.3390/ECMC2022-13470/s1.
Author Contributions
Conceptualization, A.P. (Arati Prabhu); methodology, A.P. (Amisha Punmiya) and R.G.; investigation, A.P. (Amisha Punmiya) and R.G.; formal analysis, A.P. (Amisha Punmiya), R.G. and A.P. (Arati Prabhu); resources, A.P. (Arati Prabhu); data curation, A.P. (Arati Prabhu); writing—original draft preparation, A.P. (Amisha Punmiya), R.G.; writing—review and editing, A.P. (Arati Prabhu); supervision, A.P. (Arati Prabhu); project administration, A.P. (Arati Prabhu). All authors have read and agreed to the published version of the manuscript.
Funding
This research received no external funding.
Institutional Review Board Statement
Not applicable.
Informed Consent Statement
Not applicable.
Data Availability Statement
The data presented in this study are available on request from the corresponding author.
Conflicts of Interest
The authors declare no conflict of interest.
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations. |
© 2022 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
MDPI and ACS Style
Punmiya, A.; Gharat, R.; Prabhu, A. Development of Bioactive Molecules for the Treatment of Alzheimer’s Disease. Med. Sci. Forum 2022, 14, 7. https://doi.org/10.3390/ECMC2022-13470
AMA Style
Punmiya A, Gharat R, Prabhu A. Development of Bioactive Molecules for the Treatment of Alzheimer’s Disease. Medical Sciences Forum. 2022; 14(1):7. https://doi.org/10.3390/ECMC2022-13470
Chicago/Turabian StylePunmiya, Amisha, Ruchita Gharat, and Arati Prabhu. 2022. "Development of Bioactive Molecules for the Treatment of Alzheimer’s Disease" Medical Sciences Forum 14, no. 1: 7. https://doi.org/10.3390/ECMC2022-13470
